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Introduction {#ner12843-sec-0006}
============

Significant interest has been placed on surgical site infections (SSIs) associated with implantable pain therapies including spinal cord stimulation (SCS). SSIs are associated with significant humanistic, economic, and clinical consequences. Recent publications have highlighted the consequences of SSIs for implantable pain therapies and the low levels of compliance with evidence‐based guidelines [1](#ner12843-bib-0001){ref-type="ref"}, [2](#ner12843-bib-0002){ref-type="ref"}, [3](#ner12843-bib-0003){ref-type="ref"}. An analysis of the United States Closed Claims Project data base on implantable pain therapies indicated that infection was the most common damaging event (i.e., 23% of all claims) for surgical device‐related claims [4](#ner12843-bib-0004){ref-type="ref"}.

To date, published SSI rates for SCS have ranged from 1 to 10% [1](#ner12843-bib-0001){ref-type="ref"}, [5](#ner12843-bib-0005){ref-type="ref"}, [6](#ner12843-bib-0006){ref-type="ref"}, [7](#ner12843-bib-0007){ref-type="ref"}, [8](#ner12843-bib-0008){ref-type="ref"}, [9](#ner12843-bib-0009){ref-type="ref"}, [10](#ner12843-bib-0010){ref-type="ref"}, [11](#ner12843-bib-0011){ref-type="ref"}. SSI incidence rates for implantable pain therapies have been gathered from data from retrospective and prospective studies, randomized controlled trials, and systematic reviews. Two systematic reviews have reported SCS SSI rates of 3.4--4.6% [5](#ner12843-bib-0005){ref-type="ref"}, [11](#ner12843-bib-0011){ref-type="ref"}. The number of patients in the primary studies are limited, ranging from 24 to 2737 patients [1](#ner12843-bib-0001){ref-type="ref"}, [7](#ner12843-bib-0007){ref-type="ref"}, [8](#ner12843-bib-0008){ref-type="ref"}.

Emphasis has also been placed on identifying factors that modify SSI risk for implantable pain therapies, including medical comorbidities and reoperation for battery changes or revisions. Because of the limitations of existing neuromodulation data, risk factors are often extrapolated from other surgical subspecialties. For instance, in cardiac surgery, a greater number of operations for pacemaker implantation increased the risk of SSI [12](#ner12843-bib-0012){ref-type="ref"}. In addition to medical comorbidities, previous research has suggested that SSI infections may be higher with revision and replacement surgery, especially at the site for the implantable pulse generator [13](#ner12843-bib-0013){ref-type="ref"}.

The purpose of the present study is to define and compare the infection rate for both initial and replacement SCS implants by examining a large United States payer data base. Additionally, identification of patient characteristics that increase the risk for SCS infection were sought to be determined.

Materials and Methods {#ner12843-sec-0007}
=====================

Data Source {#ner12843-sec-0008}
-----------

We utilized data from the Truven MarketScan® Commercial Claims and Encounters (CCAE) and Medicare Supplemental Databases for the study. These research data bases consist of fully adjudicated and paid insurance claims data for between 25 and 60 million individuals annually. They capture de‐identified, patient‐level health data, including clinical utilization, expenditures, patient demographic information, enrollment information, outpatient service, and outpatient prescription claims. These data bases reflect the real‐world utilization of treatment patterns and costs by linking paid claims and encounter data to detailed patient information across different sites and providers.

Study Population Selection {#ner12843-sec-0009}
--------------------------

###  {#ner12843-sec-0010}

Patient‐level data were extracted from the Marketscan CCAE Database for the years 2009--2014 and Medicare Supplemental Database for the years 2011--2014. Patients were selected for inclusion in the study if they had a record of a SCS generator implant or replacement during the study period and were more than 18 years of age (Supporting Information Table [S1](#ner12843-supitem-0001){ref-type="supplementary-material"}). The date of the first observed generator implant defined the index date for each patient. Patients were excluded if they did not meet any of the inclusion criteria, or if they had a record of other neurostimulation devices or procedures or intrathecal drug delivery systems at any point during the study period (Supporting Information Table [S2](#ner12843-supitem-0001){ref-type="supplementary-material"}). Patients were classified into one of two mutually exclusive groups 1) initial implant or 2) replacement implant. Figure [1](#ner12843-fig-0001){ref-type="fig"} outlines the algorithm to classify these patients. Patients were required to have at least 12 months of continuous medical and prescription enrollment prior to the index date. Patients with 12 months of continuous medical and pharmacy enrollment after index were included in the logistic regression analysis, and all patients were included in the survival analysis regardless of post‐index enrollment, up to 12 months post‐index date. For the survival analysis, the follow‐up period was from the index date to the earliest of either 1) the end of patient enrollment in the data or 2) the date of SCS infection.

![Attrition diagram for study patients.](NER-22-179-g001){#ner12843-fig-0001}

### Patient Infection Classification {#ner12843-sec-0011}

SCS device‐related infections were identified by either of two conditions occurring up to 365 days following SCS generator device implant. A patient had the presence of device‐related infection code as defined by *International Classification of Diseases Ninth Revision‐CM code* (ICD‐9‐CM code) 996.63 (infection and inflammatory reaction due to nervous system device, implant, and graft); orA patient had a record of a device‐related procedure code for the removal or revision of their generator implant within 12 months after index date and the presence of at least one predefined diagnosis indicating an all‐cause infection (Supporting Information Table [S3](#ner12843-supitem-0001){ref-type="supplementary-material"}) on the same date of service as the revision or removal procedure.

### Variables of Interest {#ner12843-sec-0012}

The primary outcomes of this study were the rate of SCS device‐related infection, and the risk factors associated with SCS device‐related infection. Independent variables included clinical characteristics, common comorbidities, and demographic information. Demographic information included age, gender, region, insurance type (commercial or Medicare), and group (initial implant group or replacement implant group).

The Charlson comorbidity index (CCI) was also used to estimate the health condition of patients. The CCI score uses healthcare utilization and comorbidity information recorded on the index date or \<12 months before index. The CCI code listings can be found in Supporting Information Table [S4](#ner12843-supitem-0001){ref-type="supplementary-material"}.

In addition, data on 17 specific comorbidities known to be infection risk factors in other populations were also included (Supporting Information Table [S5](#ner12843-supitem-0001){ref-type="supplementary-material"}). Each of these comorbidities was recorded on the index date or \<12 months before. Clinical characteristics including the site‐of‐service of generator implant, and the presence of any type of infection within 12 months prior to index date were examined.

Statistical Analysis {#ner12843-sec-0013}
--------------------

### Logistic Regression {#ner12843-sec-0014}

First, we examined the 6615 patients with 12 months of healthcare utilization data available after index date, which allows for a consistent picture of healthcare encounters for all patients. A descriptive analysis was performed to evaluate the infection rate at 12 months postimplant. The baseline characteristics were summarized separately for initial and replacement patients by those who experienced an infection vs. those who did not. Patient demographics, most common comorbidities, and clinical characteristics were examined using *t*‐test, chi‐square or Fisher\'s exact test. Then, a logistic regression was performed to characterize the risk factors for infection. In the logistic regression, the binary dependent variable examined was presence of infection, and other characteristics (including demographic information, comorbidities, and clinical characteristics) were assessed as independent variables in the logistic regression model. These independent variables were selected based upon previous literature suggesting their link as a potential risk factor for SSIs in the SCS, cardiac, orthopedic spine, or other literature [14](#ner12843-bib-0014){ref-type="ref"}, [15](#ner12843-bib-0015){ref-type="ref"}, [16](#ner12843-bib-0016){ref-type="ref"}, [17](#ner12843-bib-0017){ref-type="ref"}, [18](#ner12843-bib-0018){ref-type="ref"}, [19](#ner12843-bib-0019){ref-type="ref"}, [20](#ner12843-bib-0020){ref-type="ref"}, [21](#ner12843-bib-0021){ref-type="ref"}, [22](#ner12843-bib-0022){ref-type="ref"}. Analyses were performed to assess multicollinearity for all covariates; there was no evidence to show interaction among covariates.

### Survival Analysis {#ner12843-sec-0015}

We confirmed our results with a different patient population, including all 13,214 eligible SCS‐implanted patients regardless of the amount of time available after index date, using survival analyses, capturing all healthcare utilization available after index date. This analysis allows us to examine the time to infection.

First, Kaplan--Meier curves were constructed to compare the survival patterns between the initial group and the replacement group, and a log‐rank test was used to indicate whether there was any statistically significant difference between the survival curves. Then, a Cox proportional hazard regression was applied to determine the effect of various risk factors on SCS infection. The dependent variables were time and censor (value of censor was 1, which indicated an event of SCS infection, while 0 indicated censoring). The time represented follow‐up time, measured in days. The independent variables included patient demographic information (age, gender, region, etc.), comorbidities, and clinical characteristics. The Cox proportional hazard model allowed us to consider covariates in the model, thus providing us with hazard ratios (HRs) for each potential risk factor. HRs and confidence intervals were calculated and reported. Analyses were performed which confirmed that the proportional hazards assumption was satisfied.

All data were imported and maintained as SAS data files. All statistical tests used a significance level of 0.05 (*p* value \<0.05). All analyses were performed using SAS Software, Version 9.2 (SAS Institute, Inc., Cary, NC, USA).

Results {#ner12843-sec-0016}
=======

Logistic Regression {#ner12843-sec-0017}
-------------------

A total of 26,854 patients had a record of SCS generator implant or replacement during the study period. The final study population was 6615 patients after applying all inclusion and exclusion criteria. A total of 5563 (84.1%) patients were identified as the initial group, and 1052 (15.9%) patients were identified as the replacement group (Fig. [1](#ner12843-fig-0001){ref-type="fig"}).

A total of 3.11% of SCS patients (206/6615) experienced an infection event within 12 months after index date. In addition, the difference of infection rates between the initial group (3.09%; 172/5563) and the replacement group (3.23%, 34/1052) was not statistically significant (*p =* 0.8104).

The baseline characteristics for SCS patients and the results from the descriptive analysis are shown in Table [1](#ner12843-tbl-0001){ref-type="table"}. The demographic information, comorbidities, and clinical characteristics were shown by groups (initial group vs. replacement group) and by infection status (whether these patients experienced an infection event within 12 months after index date). The descriptive analysis examines factors individually to identify differences between those with and without infection. Across both cohorts, patients who experienced a device‐related infection within 12 months after generator implant were slightly younger (initial group: 51.0 \[13.6\]; replacement group: 49.8 \[9.9\]; mean \[standard deviation\]) than those who did not (53.9 \[12.7\] for initial group, and 54.3 \[13.0\] for replacement group). For patients in the initial group, patients with sleep apnea had a higher rate of infection compared with patients without (21.51 vs. 15.66%, *p* = 0.0384). For patients in the replacement group, the infection rates were higher in patients with osteoarthritis or those who had evidence of a prior infection in the 12 months before their index date than patients without (osteoarthritis: 73.53 vs. 54.22%, *p* = 0.0261; prior infection: 29.41 vs. 11.59%, *p* = 0.0018). In addition, patients with cardiac dysrhythmias had a lower rate of infection than those without (0.00 vs. 11.89%, *p* = 0.0259).

###### 

Baseline Patient Demographics and Descriptive Analysis for Initial and Replacement Cohorts by Infection Status.

                                                                         Initial group (*N* = 5563)   Replacement group (*N* = 1052)                                                                                   
  ---------------------------------------------------------------------- ---------------------------- -------------------------------- ------------------------------------------------ -------------- --------------- ------------------------------------------------
  Age (Mean \[SD\])                                                      51.0 \[13.6\]                53.9 \[12.7\]                    0.0033[\*](#ner12843-note-0003){ref-type="fn"}   49.8 \[9.9\]   54.3 \[13.0\]   0.0429[\*](#ner12843-note-0003){ref-type="fn"}
  Gender                                                                                                                                                                                                               
  Male                                                                   40.12%                       39.60%                           0.8922                                           41.18%         39.10%          0.8069
  Female                                                                 59.88%                       60.40%                           58.82%                                           60.90%                         
  Region                                                                                                                                                                                                               
  Northeast                                                              6.40%                        8.53%                            0.1304                                           14.71%         12.18%          0.1690
  North Central                                                          29.07%                       27.73%                           17.65%                                           25.93%                         
  South                                                                  52.33%                       46.34%                           35.29%                                           43.91%                         
  West                                                                   8.72%                        14.84%                           26.47%                                           15.52%                         
  Unknown                                                                3.49%                        2.56%                            5.88%                                            2.46%                          
  Insurance type                                                                                                                                                                                                       
  Commercial                                                             84.88%                       82.06%                           0.3416                                           94.12%         80.94%          0.0695
  Medicare                                                               15.12%                       17.94%                           5.88%                                            19.06%                         
  Charlson Comorbidity Index                                                                                                                                                                                           
  0                                                                      51.16%                       50.23%                           0.1562                                           44.12%         50.39%          0.2614
  1                                                                      22.67%                       25.41%                           26.47%                                           25.54%                         
  2--3                                                                   21.51%                       16.51%                           14.71%                                           17.78%                         
  ≥4                                                                     4.65%                        7.85%                            14.71%                                           6.29%                          
  Cardiac dysrhythmias                                                                                                                                                                                                 
  Yes                                                                    8.14%                        10.89%                           0.2529                                           0.00%          11.89%          0.0259[\*](#ner12843-note-0003){ref-type="fn"}
  No                                                                     91.86%                       89.11%                           100.00%                                          88.11%                         
  Congestive heart failure                                                                                                                                                                                             
  Yes                                                                    2.33%                        3.06%                            0.8202                                           2.94%          3.93%           1.0000
  No                                                                     97.67%                       96.94%                           97.06%                                           96.07%                         
  COPD                                                                                                                                                                                                                 
  Yes                                                                    10.47%                       11.09%                           0.7963                                           14.71%         10.12%          0.3841
  No                                                                     89.53%                       88.91%                           85.29%                                           89.88%                         
  Depressive disorders                                                                                                                                                                                                 
  Yes                                                                    50.00%                       46.87%                           0.4188                                           44.12%         36.35%          0.3547
  No                                                                     50.00%                       53.13%                           55.88%                                           63.65%                         
  Diabetes type 1                                                                                                                                                                                                      
  Yes                                                                    4.07%                        3.32%                            0.5904                                           8.82%          3.63%           0.1352
  No                                                                     95.93%                       96.68%                           91.18%                                           96.37%                         
  Diabetes type 2                                                                                                                                                                                                      
  Yes                                                                    24.42%                       22.02%                           0.4551                                           20.59%         19.74%          0.9033
  No                                                                     75.58%                       77.98%                           79.41%                                           80.26%                         
  GERD                                                                                                                                                                                                                 
  Yes                                                                    18.60%                       21.59%                           0.3479                                           14.71%         21.41%          0.3464
  No                                                                     81.40%                       78.41%                           85.29%                                           78.59%                         
  Hyperlipidemia                                                                                                                                                                                                       
  Yes                                                                    43.02%                       42.48%                           0.8868                                           41.18%         39.69%          0.8613
  No                                                                     56.98%                       57.52%                           58.82%                                           60.31%                         
  Hypertension                                                                                                                                                                                                         
  Yes                                                                    58.14%                       55.26%                           0.4544                                           50.00%         50.10%          0.9910
  No                                                                     41.86%                       44.74%                           50.00%                                           49.90%                         
  Hypothyroidism                                                                                                                                                                                                       
  Yes                                                                    13.95%                       16.06%                           0.4574                                           20.59%         15.72%          0.4445
  No                                                                     86.05%                       83.94%                           79.41%                                           84.28%                         
  Lumbar disk disease                                                                                                                                                                                                  
  Yes                                                                    75.58%                       69.67%                           0.0964                                           58.82%         50.69%          0.3506
  No                                                                     24.42%                       30.33%                           41.18%                                           49.31%                         
  Overweight and obesity                                                                                                                                                                                               
  Yes                                                                    14.53%                       13.56%                           0.7133                                           14.71%         11.49%          0.5649
  No                                                                     85.47%                       86.44%                           85.29%                                           88.51%                         
  Osteoarthritis                                                                                                                                                                                                       
  Yes                                                                    70.35%                       67.35%                           0.4091                                           73.53%         54.22%          0.0261[\*](#ner12843-note-0003){ref-type="fn"}
  No                                                                     29.65%                       32.65%                           26.47%                                           45.78%                         
  Other coronary artery disease                                                                                                                                                                                        
  Yes                                                                    13.37%                       12.32%                           0.6788                                           11.76%         10.90%          0.7816
  No                                                                     86.63%                       87.68%                           88.24%                                           89.10%                         
  Peripheral vascular disease                                                                                                                                                                                          
  Yes                                                                    6.98%                        5.12%                            0.2792                                           11.76%         4.72%           0.0821
  No                                                                     93.02%                       94.88%                           88.24%                                           95.28%                         
  Sleep apnea                                                                                                                                                                                                          
  Yes                                                                    21.51%                       15.66%                           0.0384[\*](#ner12843-note-0003){ref-type="fn"}   11.76%         14.83%          0.8070
  No                                                                     78.49%                       84.34%                           88.24%                                           85.17%                         
  Smoking                                                                                                                                                                                                              
  Yes                                                                    14.53%                       14.43%                           0.9697                                           20.59%         12.28%          0.1502
  No                                                                     85.47%                       85.57%                           79.41%                                           87.72%                         
  Evidence of prior infection within 12‐month period before index date                                                                                                                                                 
  Yes                                                                    12.79%                       9.98%                            0.2277                                           29.41%         11.59%          0.0018[\*](#ner12843-note-0003){ref-type="fn"}
  No                                                                     87.21%                       90.02%                           70.59%                                           88.41%                         
  Setting of service on the index date                                                                                                                                                                                 
  Outpatient                                                             68.02%                       71.55%                           0.6166                                           44.12%         63.36%          0.0994
  ASC                                                                    10.47%                       10.41%                           14.71%                                           10.31%                         
  Inpatient                                                              5.81%                        5.79%                            8.82%                                            6.29%                          
  Other                                                                  5.81%                        3.67%                            2.94%                                            4.42%                          
  Unknown                                                                9.88%                        8.59%                            29.41%                                           15.62%                         

*p* \< 0.05.

Logistic regression results (*n* = 6615) are shown in Table [2](#ner12843-tbl-0002){ref-type="table"} and demonstrate which characteristics are most likely to be risk factors when considering all factors together. The regression identified that risk factors for SCS device‐related infection include a comorbidity of peripheral vascular disease (OR, 1.784; 95% CI: 1.011--3.149; *p* = 0.0457) as well as a history of previous (all‐cause) infection in the 12‐month period prior to SCS implant (OR, 1.518; 95% CI: 1.022--2.254; *p* = 0.0386). Elderly patients were less likely to have infection; for each additional year of age at any timepoint, patients are 3.2% less likely to have an infection (OR, 0.968; 95% CI: 0.952--0.984; *p* \< 0.0001; Table [3](#ner12843-tbl-0003){ref-type="table"}) which is true regardless of age group division chosen. Notably, there were no observed differences for rate of infection when looking at insurance type or setting of service of the index implant.

###### 

The Result of Logistic Regression for Infection Within 12 Months After Index Date.

                                                                         Odds ratio   95% confidenceinterval   *p* value   
  ---------------------------------------------------------------------- ------------ ------------------------ ----------- --------------------------------------------------
  Age                                                                    0.968        0.952                    0.984       \<0.0001[\*](#ner12843-note-0004){ref-type="fn"}
  Gender                                                                                                                   
  Male                                                                   0.975        0.723                    1.316       0.8697
  Female                                                                 Reference                                         
  Region                                                                                                                   
  Northeast                                                              0.808        0.470                    1.388       0.4403
  North Central                                                          0.974        0.695                    1.366       0.8797
  South                                                                  Reference                                         
  West                                                                   0.760        0.481                    1.200       0.2389
  Unknown                                                                1.404        0.665                    2.964       0.3738
  Insurance type                                                                                                           
  Commercial                                                             0.729        0.419                    1.269       0.2639
  Medicare                                                               Reference                                         
  Charlson Comorbidity Index                                                                                               
  0                                                                      Reference                                         
  1                                                                      0.868        0.583                    1.292       0.4855
  2--3                                                                   1.108        0.682                    1.801       0.6780
  ≥4                                                                     0.659        0.300                    1.445       0.2979
  Group                                                                                                                    
  Initial group                                                          0.882        0.602                    1.295       0.5225
  Replacement group                                                      Reference                                         
  Setting of service on the index date                                                                                     
  Outpatient                                                             Reference                                         
  Ambulatory surgical center                                             1.229        0.779                    1.938       0.3747
  Inpatient                                                              1.204        0.671                    2.160       0.5330
  Other                                                                  1.457        0.772                    2.750       0.2454
  Unknown                                                                1.521        0.987                    2.344       0.0572
  Cardiac dysrhythmias                                                                                                     
  Yes                                                                    0.588        0.334                    1.034       0.0653
  No                                                                     Reference                                         
  Congestive heart failure                                                                                                 
  Yes                                                                    0.773        0.297                    2.011       0.5973
  No                                                                     Reference                                         
  Chronic obstructive pulmonary disease (COPD)                                                                             
  Yes                                                                    1.072        0.650                    1.766       0.7857
  No                                                                     Reference                                         
  Depressive disorders                                                                                                     
  Yes                                                                    1.057        0.794                    1.407       0.7035
  No                                                                     Reference                                         
  Diabetes 1                                                                                                               
  Yes                                                                    1.335        0.642                    2.775       0.4391
  No                                                                     Reference                                         
  Diabetes 2                                                                                                               
  Yes                                                                    1.124        0.716                    1.762       0.6121
  No                                                                     Reference                                         
  GERD                                                                                                                     
  Yes                                                                    0.779        0.537                    1.129       0.1869
  No                                                                     Reference                                         
  Hyperlipidemia                                                                                                           
  Yes                                                                    1.061        0.774                    1.454       0.7145
  No                                                                     Reference                                         
  Hypertension                                                                                                             
  Yes                                                                    1.245        0.903                    1.718       0.1814
  No                                                                     Reference                                         
  Hypothyroidism                                                                                                           
  Yes                                                                    0.974        0.651                    1.458       0.8987
  No                                                                     Reference                                         
  Lumbar disk disease                                                                                                      
  Yes                                                                    1.298        0.936                    1.799       0.1177
  No                                                                     Reference                                         
  Overweight and obesity                                                                                                   
  Yes                                                                    0.942        0.621                    1.428       0.7781
  No                                                                     Reference                                         
  Osteoarthritis                                                                                                           
  Yes                                                                    1.346        0.976                    1.856       0.0699
  No                                                                     Reference                                         
  Other coronary artery disease                                                                                            
  Yes                                                                    1.221        0.765                    1.950       0.4031
  No                                                                     Reference                                         
  Peripheral vascular disease                                                                                              
  Yes                                                                    1.784        1.011                    3.149       0.0457[\*](#ner12843-note-0004){ref-type="fn"}
  No                                                                     Reference                                         
  Sleep apnea                                                                                                              
  Yes                                                                    1.268        0.869                    1.849       0.2175
  No                                                                     Reference                                         
  Smoking                                                                                                                  
  Yes                                                                    0.992        0.667                    1.476       0.9682
  No                                                                     Reference                                         
  Evidence of prior infection within 12‐month period before index date                                                     
  Yes                                                                    1.518        1.022                    2.254       0.0386[\*](#ner12843-note-0004){ref-type="fn"}
  No                                                                     Reference                                         

*p* \< 0.05.

###### 

Infection Rate Distribution by Age Group.

           InfectionYes (*N* = 206)   InfectionNo (*N* = 6409)   \% w/ Infection inthis age group
  -------- -------------------------- -------------------------- ----------------------------------
  18--29   8                          139                        5.44
  30--44   60                         1277                       4.49
  45--64   113                        3900                       2.82
  ≥65      25                         1093                       2.24
  Total    206                        6409                       3.11

Survival Analysis {#ner12843-sec-0018}
-----------------

For the survival analysis, we identified all SCS‐implanted patients, but we did not require that patients have any period of continuous enrollment after index date. After all inclusion and exclusion criteria, the final study population was 13,214 patients. A total of 11,176 (84.6%) patients were identified as the initial group, and 2038 (15.4%) patients were identified as the replacement group. The attrition of SCS population selection for this study is shown in Figure [1](#ner12843-fig-0001){ref-type="fig"}.

The patient demographic information and other baseline characteristics for patients in the survival analysis cohort are shown in Table [4](#ner12843-tbl-0004){ref-type="table"}. In the initial group, patients who experienced the SCS infection events were slightly younger than patients who did not (51.6 \[13.5\] vs. 54.2 \[12.8\], respectively). Except for age, we identified that there were no statistically significant demographic differences between patients with SCS infection and patients without in either group. Across both cohorts, if patients had evidence of an infection in the 12 months before their index date, they had a significantly higher likelihood to experience SCS infection than patients without an infection before index (in the initial group: 18.09 vs. 10.98%, *p* = 0.0001; in the replacement group: 23.08 vs. 12.29%, *p* = 0.0205). For patients in the replacement group, the infection rates were higher patients who smoked than patients who did not smoke (25.00 vs. 12.29%, *p* = 0.0169).

###### 

Patient Demographics and Comorbid Conditions for Initial and Replacement Cohorts by Infection Status, Survival Analysis.

                                                                     Initial group (*N* = 11,176)   Replacement group (*N* = 2038)                                                                                    
  ------------------------------------------------------------------ ------------------------------ -------------------------------- ------------------------------------------------ --------------- --------------- ------------------------------------------------
  Age (Mean \[SD\])                                                  51.6 \[13.5\]                  54.2 \[12.8\]                    0.0006[\*](#ner12843-note-0005){ref-type="fn"}   51.3 \[12.1\]   54.0 \[13.4\]   0.1603
  Gender                                                                                                                                                                                                              
  Male                                                               38.23%                         40.49%                           0.4367                                           63.46%          61.28%          0.7497
  Female                                                             61.77%                         59.51%                           36.54%                                           38.72%                          
  Region                                                                                                                                                                                                              
  Northeast                                                          10.24%                         9.72%                            0.5134                                           17.31%          13.70%          0.2505
  North Central                                                      27.65%                         26.89%                           21.15%                                           26.23%                          
  South                                                              48.46%                         46.87%                           34.62%                                           42.75%                          
  West                                                               10.58%                         14.09%                           23.08%                                           15.21%                          
  Unknown                                                            3.07%                          2.43%                            3.85%                                            2.11%                           
  Insurance type                                                                                                                                                                                                      
  Commercial                                                         84.98%                         82.00%                           0.1889                                           86.54%          81.72%          0.3738
  Medicare                                                           15.02%                         18.00%                           13.46%                                           18.28%                          
  Setting of service on the index date                                                                                                                                                                                
  Outpatient                                                         70.99%                         71.92%                           0.3948                                           50.00%          64.80%          0.0747
  ASC                                                                9.22%                          11.46%                           19.23%                                           11.23%                          
  Inpatient                                                          5.80%                          5.59%                            5.77%                                            5.99%                           
  Other                                                              5.12%                          3.51%                            1.92%                                            4.33%                           
  Unknown                                                            8.87%                          7.53%                            23.08%                                           13.65%                          
  Charlson Comorbidity Index                                                                                                                                                                                          
  0                                                                  47.78%                         47.95%                           0.2086                                           40.38%          48.39%          0.1305
  1                                                                  21.84%                         25.90%                                                                            23.08%          25.73%          
  2--3                                                               21.84%                         17.72%                                                                            21.15%          18.73%          
  ≥4                                                                 8.53%                          8.43%                                                                             15.38%          7.15%           
  Cardiac dysrhythmias                                                                                                                                                                                                
  Yes                                                                12.29%                         12.02%                           0.8893                                           11.54%          11.78%          0.9570
  No                                                                 87.71%                         87.98%                                                                            88.46%          88.22%          
  Congestive heart failure                                                                                                                                                                                            
  Yes                                                                4.10%                          3.75%                            0.7582                                           5.77%           4.28%           0.4893
  No                                                                 95.90%                         96.25%                                                                            94.23%          95.72%          
  COPD                                                                                                                                                                                                                
  Yes                                                                10.24%                         11.61%                           0.4677                                           11.54%          12.19%          0.8880
  No                                                                 89.76%                         88.39%                                                                            88.46%          87.81%          
  Depressive disorders                                                                                                                                                                                                
  Yes                                                                50.17%                         48.41%                           0.5529                                           44.23%          39.12%          0.4566
  No                                                                 49.83%                         51.59%                                                                            55.77%          60.88%          
  Diabetes type 1                                                                                                                                                                                                     
  Yes                                                                4.44%                          3.41%                            0.3405                                           7.69%           3.73%           0.1351
  No                                                                 95.56%                         96.59%                                                                            92.31%          96.27%          
  Diabetes type 2                                                                                                                                                                                                     
  Yes                                                                25.60%                         22.95%                           0.2887                                           23.08%          21.35%          0.7643
  No                                                                 74.40%                         77.05%                                                                            76.92%          78.65%          
  GERD                                                                                                                                                                                                                
  Yes                                                                21.84%                         23.29%                           0.5620                                           13.46%          23.56%          0.0889
  No                                                                 78.16%                         76.71%                                                                            86.54%          76.44%          
  Hyperlipidemia                                                                                                                                                                                                      
  Yes                                                                44.37%                         44.72%                           0.9047                                           42.31%          43.76%          0.8353
  No                                                                 55.63%                         55.28%                                                                            57.69%          56.24%          
  Hypertension                                                                                                                                                                                                        
  Yes                                                                59.73%                         56.86%                           0.3280                                           48.08%          52.92%          0.4898
  No                                                                 40.27%                         43.14%                                                                            51.92%          47.08%          
  Hypothyroidism                                                                                                                                                                                                      
  Yes                                                                13.31%                         16.17%                           0.1884                                           17.31%          17.72%          0.9381
  No                                                                 86.69%                         83.83%                                                                            82.69%          82.28%          
  Lumbar disk disease                                                                                                                                                                                                 
  Yes                                                                75.77%                         70.98%                           0.0745                                           59.62%          52.22%          0.2915
  No                                                                 24.23%                         29.02%                                                                            40.38%          47.78%          
  Overweight and obesity                                                                                                                                                                                              
  Yes                                                                17.41%                         15.85%                           0.4723                                           17.31%          13.80%          0.4698
  No                                                                 82.59%                         84.15%                                                                            82.69%          86.20%          
  Osteoarthritis                                                                                                                                                                                                      
  Yes                                                                72.35%                         70.04%                           0.3922                                           65.38%          56.95%          0.2249
  No                                                                 27.65%                         29.96%                                                                            34.62%          43.05%          
  Other coronary artery disease                                                                                                                                                                                       
  Yes                                                                12.63%                         13.10%                           0.8120                                           11.54%          11.68%          0.9747
  No                                                                 87.37%                         86.90%                                                                            88.46%          88.32%          
  Peripheral vascular disease                                                                                                                                                                                         
  Yes                                                                6.83%                          5.41%                            0.2927                                           9.62%           4.63%           0.0957
  No                                                                 93.17%                         94.59%                                                                            90.38%          95.37%          
  Sleep apnea                                                                                                                                                                                                         
  Yes                                                                20.48%                         16.88%                           0.1054                                           15.38%          16.16%          0.8803
  No                                                                 79.52%                         83.12%                                                                            84.62%          83.84%          
  Smoking                                                                                                                                                                                                             
  Yes                                                                13.99%                         16.81%                           0.2031                                           25.00%          13.44%          0.0169[\*](#ner12843-note-0005){ref-type="fn"}
  No                                                                 86.01%                         83.19%                                                                            75.00%          86.56%          
  Evidence of prior infection in 12‐month period before index date                                                                                                                                                    
  Yes                                                                18.09%                         10.98%                           0.0001[\*](#ner12843-note-0005){ref-type="fn"}   23.08%          12.29%          0.0205[\*](#ner12843-note-0005){ref-type="fn"}
  No                                                                 81.91%                         89.02%                                                                            76.92%          87.71%          

*p* \< 0.05.

The Kaplan--Meier curves (Fig. [2](#ner12843-fig-0002){ref-type="fig"}), indicate that the SCS infection rates were 3.15% in the initial group and 2.96% in the replacement group at the end of 12 months after index date. The result of the log‐rank test showed the difference in infection rates between the initial group and the replacement group was not statistically significant (*p* = 0.7916). Approximately, 40% of infections occurred within the first 30 days and approximately three‐quarters occurred within the first 90 days after generator implant.

![Kaplan--Meier curves of infection rate among initial and replacement groups.](NER-22-179-g002){#ner12843-fig-0002}

From Table [5](#ner12843-tbl-0005){ref-type="table"}, the result of the COX proportional hazard regression (*n* = 13,214) identified risk factors for SCS device‐related infection when all factors were considered together, including a comorbidity of lumbar disk disease (HR, 1.302; 95% CI: 1.015--1.671; *p* = 0.0381) as well as a history of prior infection (HR, 1.770; 95% CI: 1.342--2.336; *p* \< 0.0001). In addition, elderly patients were less likely to have an infection (HR, 0.974; 95% CI: 0.962--0.986; *p* \< 0.0001). In other words, for each additional year of age at any timepoint, patients were 2.6% less likely to have a SCS infection. Several factors that were significant in the descriptive analysis were not significant when examined along with the other factors in the COX proportional hazard regression analysis.

###### 

The Result of COX Proportional Hazard Regression Model.

                                                                         Hazardratio   95% confidence interval   *p* value   
  ---------------------------------------------------------------------- ------------- ------------------------- ----------- --------------------------------------------------
  Age                                                                    0.974         0.962                     0.986       \<0.0001[\*](#ner12843-note-0006){ref-type="fn"}
  Gender                                                                                                                     
  Male                                                                   0.861         0.685                     1.083       0.2010
  Female                                                                 Reference                                           
  Region                                                                                                                     
  Northeast                                                              1.103         0.775                     1.572       0.5861
  North Central                                                          1.017         0.785                     1.318       0.8985
  South                                                                  Reference                                           
  West                                                                   0.877         0.624                     1.233       0.4501
  Unknown                                                                1.282         0.695                     2.367       0.4265
  Insurance type                                                                                                             
  Commercial                                                             0.803         0.534                     1.208       0.2923
  Medicare                                                               Reference                                           
  Charlson Comorbidity Index                                                                                                 
  0                                                                      Reference                                           
  1                                                                      0.898         0.665                     1.213       0.4833
  2--3                                                                   1.327         0.939                     1.874       0.1089
  ≥4                                                                     1.198         0.710                     2.021       0.4988
  Group                                                                                                                      
  Initial group                                                          1.006         0.744                     1.358       0.9710
  Replacement group                                                      Reference                                           
  Setting of service on the index date                                                                                       
  Outpatient                                                             Reference                                           
  Ambulatory surgical center                                             1.004         0.708                     1.423       0.9834
  Inpatient                                                              1.057         0.669                     1.671       0.8129
  Other                                                                  1.238         0.744                     2.060       0.4105
  Unknown                                                                1.296         0.914                     1.837       0.1454
  Cardiac dysrhythmias                                                                                                       
  Yes                                                                    1.016         0.724                     1.426       0.9259
  No                                                                     Reference                                           
  Congestive heart failure                                                                                                   
  Yes                                                                    1.065         0.606                     1.874       0.8261
  No                                                                     Reference                                           
  Chronic obstructive pulmonary disease (COPD)                                                                               
  Yes                                                                    0.816         0.556                     1.196       0.2976
  No                                                                     Reference                                           
  Depressive disorders                                                                                                       
  Yes                                                                    1.018         0.820                     1.264       0.8719
  No                                                                     Reference                                           
  Diabetes 1                                                                                                                 
  Yes                                                                    1.147         0.668                     1.972       0.6185
  No                                                                     Reference                                           
  Diabetes 2                                                                                                                 
  Yes                                                                    1.014         0.730                     1.409       0.9327
  No                                                                     Reference                                           
  GERD                                                                                                                       
  Yes                                                                    0.840         0.643                     1.098       0.2028
  No                                                                     Reference                                           
  Hyperlipidemia                                                                                                             
  Yes                                                                    1.031         0.811                     1.310       0.8024
  No                                                                     Reference                                           
  Hypertension                                                                                                               
  Yes                                                                    1.172         0.914                     1.501       0.2105
  No                                                                     Reference                                           
  Hypothyroidism                                                                                                             
  Yes                                                                    0.804         0.587                     1.101       0.1744
  No                                                                     Reference                                           
  Lumbar disk disease                                                                                                        
  Yes                                                                    1.302         1.015                     1.671       0.0381[\*](#ner12843-note-0006){ref-type="fn"}
  No                                                                     Reference                                           
  Overweight and obesity                                                                                                     
  Yes                                                                    1.027         0.767                     1.376       0.8581
  No                                                                     Reference                                           
  Osteoarthritis                                                                                                             
  Yes                                                                    1.207         0.944                     1.544       0.1329
  No                                                                     Reference                                           
  Other coronary artery disease                                                                                              
  Yes                                                                    0.976         0.677                     1.407       0.8975
  No                                                                     Reference                                           
  Peripheral vascular disease                                                                                                
  Yes                                                                    1.385         0.891                     2.151       0.1476
  No                                                                     Reference                                           
  Sleep apnea                                                                                                                
  Yes                                                                    1.191         0.895                     1.585       0.2293
  No                                                                     Reference                                           
  Smoking                                                                                                                    
  Yes                                                                    0.903         0.670                     1.217       0.5029
  No                                                                     Reference                                           
  Evidence of prior infection within 12‐month period before index date                                                       
  Yes                                                                    1.770         1.342                     2.336       \<0.0001[\*](#ner12843-note-0006){ref-type="fn"}
  No                                                                     Reference                                           

*p* \< 0.05

Discussion {#ner12843-sec-0019}
==========

Prevention of infection with SCS implants and replacement procedures is of the utmost importance. Consequences of these events have been well reported and are a detriment to the field, although levels of compliance with evidence‐based guidelines remain low [1](#ner12843-bib-0001){ref-type="ref"}, [3](#ner12843-bib-0003){ref-type="ref"}. SSI rates have been reported in the literature and can range from 1 to 10%, but have most commonly been accepted to be 3--4.6% [1](#ner12843-bib-0001){ref-type="ref"}, [3](#ner12843-bib-0003){ref-type="ref"}, [7](#ner12843-bib-0007){ref-type="ref"}, [9](#ner12843-bib-0009){ref-type="ref"}, [23](#ner12843-bib-0023){ref-type="ref"}, [24](#ner12843-bib-0024){ref-type="ref"}, [25](#ner12843-bib-0025){ref-type="ref"}, [26](#ner12843-bib-0026){ref-type="ref"}, [27](#ner12843-bib-0027){ref-type="ref"}, [28](#ner12843-bib-0028){ref-type="ref"}. However, most studies are retrospective and have smaller sample sizes. In addition, there is limited attention to the characteristics involved that lead to infection, as well as differences between initial and replacement procedures.

Our present study sought to define and compare the infection rates for both initial and replacement SCS implants and identify patient characteristics that increase the risk for SCS infection. This is the largest study to date that examines the SCS device‐related infection rate. We examined a large United States payer data base to provide real‐world data in which the survival analysis included 13,214 patients while the logistic regression included 6615 patients. The data demonstrated a 3% device‐related infection rate within 12 months of SCS implant, with most infections occurring within the first 90 days following device implantation (Fig. [2](#ner12843-fig-0002){ref-type="fig"}). This infection rate is in line with previous published data, while the time to occurrence of infection is similar to the reported rate by Hayek et al. which demonstrate a median time to infection of 1.99 months[1](#ner12843-bib-0001){ref-type="ref"}, [7](#ner12843-bib-0007){ref-type="ref"}, [24](#ner12843-bib-0024){ref-type="ref"}. In addition, our data demonstrated no statistically significant difference between the likelihood of infection for patients with initial implants and replacement implants.

Attention in this analysis is largely placed on identifying the factors that may contribute to an increased risk of SSI for SCS, including medical comorbidities and revisions. Many of these risk factors have been identified by extrapolating data from other surgical procedures, such as pacemaker implantation, which demonstrated higher risk of SSI with replacement procedures, but this did not hold true in our analysis. The logistic regression analysis included patients with 12 months of continuous enrollment after the index date and identified a comorbidity of PVD as well as history of a previous infection in the 12‐month period prior to index as risk factors for SCS infection. Interestingly, it also demonstrated that older patients were less likely to have infections and that infection was less likely with increasing age. This has been identified in other procedures; two recent analysis of total ankle arthroplasties concluded that age also had a protective effect against infections [16](#ner12843-bib-0016){ref-type="ref"}, [29](#ner12843-bib-0029){ref-type="ref"}. Future research is needed to further explore the impact of age on infection risk in this patient population.

The survival analysis included a very large sample size, nearly doubling the population of patients compared to the logistic regression analysis, given that continuous enrollment for 12 months after the procedure was not necessary. This is an important way to look at patients when exploring a safety endpoint to validate that the safety event does not cause patients to drop out of the data. The results are similar to the logistic regression analysis, confirming that history of prior infection was identified as a risk factor for an infection and that younger patients were more likely to have an infection. The rate of infection also was consistent in the two different patient populations.

In this study, some factors such as smoking, cardiac dysrhythmias, or sleep apnea were individually significant in the descriptive analysis for either the initial or replacement group of patients but were no longer statistically significant in the final regression models. The descriptive analysis is designed to assess differences between the groups, while the multiple regression model is used to evaluate risk factors driving the occurrence of infection while looking at all the characteristics together. Characteristics are considered risk factors when they are found to be significant in these regression models. The physician authors recommend that clinicians closely examine patients with the factors that were individually significant and assess them in context with other comorbidities to determine if the overall combination may warrant additional infection prevention mechanisms, particularly as some of these factors have been identified as associated with infection in other disease states [30](#ner12843-bib-0030){ref-type="ref"}.

As confirmed in both the logistic regression and survival analysis, the expected risk factors for developing an SSI such as obesity, diabetes, and smoking were not identified as risk factors with this dataset, although smoking was found to individually increase the risk in those undergoing replacement procedures. A recent large retrospective chart analysis demonstrated similar conclusions [7](#ner12843-bib-0007){ref-type="ref"}. Future prospective studies with large study populations are needed to further assess the impact of these individual risk factors on SSIs with implantable pain therapies. The evolving consideration of appropriate candidates for elective surgery and related management of chronic disease characteristics prior to surgery may be at play in this recent dataset compared with prior analyses [1](#ner12843-bib-0001){ref-type="ref"}.

The current study is a retrospective analysis of SCS device‐related infection. A large international survey indicated low compliance with evidence‐based infection control practices by implanting physicians during the timeframe under review in this study [3](#ner12843-bib-0003){ref-type="ref"}. Evidence‐based guidelines have been published to increase adherence to established standards [1](#ner12843-bib-0001){ref-type="ref"}. This article identifies patients in whom greater care may be appropriate. Clinicians should consider following best‐practice recommendations to prevent and control infections in all patients, particularly patients at greater risk for infection.

This study examining a United States payer data base demonstrates that research is warranted on methods to limit SCS infection rates. This is especially true in those with a comorbidity of PVD, history of previous infection, and those of younger age. Future studies utilizing a different time period may identify the impact of increased compliance with infection control practices and the evolving infection control field. This research also highlights the need for a prospective analysis in the field of SCS to further understand patients at higher risk for infection. Ultimately, this study highlights the need for strong infection prevention, especially in those with prior infections.

Limitations do exist in this study despite the large sample size looking at real‐world data. This study is a retrospective cohort analysis using administrative claims data sourced for billing purposes and is therefore reliant on proper coding and documentation. This assumption may not always include accurate and complete coding. Perhaps, the most important limiting factor is that important comorbidities such as obesity and smoking history may not be properly or accurately coded leading to underreporting; these factors are known to be underreported in administrative claims data [31](#ner12843-bib-0031){ref-type="ref"}, [32](#ner12843-bib-0032){ref-type="ref"}, [33](#ner12843-bib-0033){ref-type="ref"}, [34](#ner12843-bib-0034){ref-type="ref"}. Infection classification using ICD‐9 diagnosis codes from claims data does not permit further classification of device‐related infection reasons or severity in a similar manner to clinical studies, which may categorize factors contributing to device‐related infection into hardware, therapy, biological, procedure, medication, or human‐related factors; this classification is not possible in this claims dataset and likely includes instances of all of those factors grouped together. Some factors identified as SSI risk factors in previous studies such as surgical time are not available in this dataset [35](#ner12843-bib-0035){ref-type="ref"}. Last, this analysis follows patients for a 12 month period after implantation which does not account for potential bacterial seeding of the implant far after the implant. Despite these limitations, this study is a valuable contribution to understanding infection rates, examining real‐world effectiveness and complications of SCS therapy.

Conclusion {#ner12843-sec-0020}
==========

The approximate 3% device‐related infection rate within 12 months of SCS implant determined from a large administrative data base further emphasizes the need for improvement in SCS infection control practices. Based on these results, research is warranted on methods to limit SCS infection rates in patients with a history of prior infection, as well as younger patient populations. Further research is needed to evaluate these patient factors in a prospective manner for SCS.
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COMMENT {#ner12702-sec-1015}
=======

This study provides useful clinical information that identifies those patients at a potentially higher risk of surgical site infections after implantation of spinal cord stimulators (SCS). Specifically, this study highlights that we must be cognizant of the higher infection risk of young patients, and those with a prior infection history receiving a SCS implant.

Troy Cross, PhD

*Rochester, NY, USA*
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###### 

**Table S1** lists the procedure codes for SCS‐related procedures that were used to identify the study population.

**Table S2** lists the procedure codes for other neurostimulation or intrathecal drug delivery devices, used as exclusion criteria.

**Table S3** details the infection categorization used for identification of device‐related infection for the analysis.

**Table S4** details the conditions included in the Charlson Comorbidity Index and details the corresponding ICD‐9 diagnosis codes.

**Table S5** details the comorbidity risk factors used in this study.

###### 

Click here for additional data file.
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